Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robbie Majzner

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Pediatrics|December 1, 2017
New developments in immunotherapy for pediatric solid tumorsLiora M Schultz, Robbie Majzner, Kara L Davis, et al.
Transplantation and Cellular Therapy|April 8, 2024
INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young AdultsAimee C Talleur, Vanessa A Fabrizio, Richard Aplenc, et al.
Journal for Immunotherapy of Cancer|May 2, 2018
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cellsAnandani Nellan, Christopher Rota, Robbie Majzner, et al.
Nature|December 6, 2019
c-Jun overexpression in CAR T cells induces exhaustion resistanceRachel C Lynn, Evan W Weber, Elena Sotillo, et al.
British Journal of Haematology|February 9, 2012
T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipientsMark B Geyer, Angela M Ricci, Judith S Jacobson, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 29, 2024
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Pediatrics|December 1, 2017
New developments in immunotherapy for pediatric solid tumorsLiora M Schultz, Robbie Majzner, Kara L Davis, et al.
Transplantation and Cellular Therapy|April 8, 2024
INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young AdultsAimee C Talleur, Vanessa A Fabrizio, Richard Aplenc, et al.
Journal for Immunotherapy of Cancer|May 2, 2018
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cellsAnandani Nellan, Christopher Rota, Robbie Majzner, et al.
Nature|December 6, 2019
c-Jun overexpression in CAR T cells induces exhaustion resistanceRachel C Lynn, Evan W Weber, Elena Sotillo, et al.
British Journal of Haematology|February 9, 2012
T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipientsMark B Geyer, Angela M Ricci, Judith S Jacobson, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 29, 2024
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 1